Response and resistance factor candidates to HER2 targeted therapy in gastric cancer (GC)

被引：0
|
作者：
Lordick, F. [1 ]
Haffner, I. [1 ]
Luber, B. [2 ]
Maier, D. [3 ]
Kretzschmar, A. [4 ]
von Weikersthal, L. Fischer [5 ]
Riera-Knorrenschild, J. [6 ]
Ahlborn, M. [7 ]
Schierle, K. [8 ]
Wittekind, C. [8 ]
机构：
[1] Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, Germany
[2] Tech Univ Munich, Munich, Germany
[3] Biomax Informat AG, Planegg, Germany
[4] MVZ Mitte Onkol Schwerpunktpraxis, Leipzig, Germany
[5] Gesundheitszentrum St Marien GmbH, Dept Oncol, Amberg, Germany
[6] Univ Klinikum Giessen & Marburg, Marburg, Germany
[7] Klinikum Braunschweig, Braunschweig, Germany
[8] Univ Hosp Leipzig, Pathol, Leipzig, Germany
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD-005
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [21] Her2 a paradigm for targeted therapy
    Marijon, Helene
    Andre, Fabrice
    BULLETIN DU CANCER, 2011, 98 (09) : 1011 - 1017
  • [22] Targeted therapy for HER2 driven colorectal cancer.
    Ross, Jeffrey S.
    Ali, Siraj Mahamed
    Elvin, Julia Andrea
    Schrock, Alexa Betzig
    Suh, James
    Vergilio, Jo-Anne
    Ramkissoon, Shakti
    Severson, Eric Allan
    Daniel, Sugganth
    Fabrizio, David
    Frampton, Garrett Michael
    Miller, Vincent A.
    Stephens, Philip J.
    Gay, Laurie M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] The role of HER2 in cancer therapy and targeted drug delivery
    Tai, Wanyi
    Mahato, Rubi
    Cheng, Kun
    JOURNAL OF CONTROLLED RELEASE, 2010, 146 (03) : 264 - 275
  • [24] Development of HER2 targeted therapy
    Tamura, Kenji
    CANCER SCIENCE, 2021, 112 : 158 - 158
  • [25] HER2 targeted therapy in colorectal cancer: New horizons
    Suwaidan, Ali Abdulnabi
    Lau, David K.
    Chau, Ian
    CANCER TREATMENT REVIEWS, 2022, 105
  • [26] Human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC): results of the ToGA trial screening programme and recommendations for HER2 testing
    Chung, H.
    Bang, Y. J.
    Xu, J. M.
    Lordick, F.
    Sawaki, A.
    Lipatov, O.
    Lehle, M.
    Pickl, M.
    Rueschoff, J.
    Van Cutsem, E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 364 - 364
  • [27] KRAS status and HER2 targeted treatment in advanced gastric cancer
    Shinozaki, E.
    Osumi, H.
    Chin, K.
    Takahari, D.
    Ogura, M.
    Ichimura, T.
    Matsushima, T.
    Wakatsuki, T.
    Nakayama, I.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] KRAS status and HER2 targeted treatment in advanced gastric cancer
    Shinozaki, E.
    Osumi, H.
    Chin, K.
    Ogura, M.
    Takahari, D.
    Ichimura, T.
    Matsushima, T.
    Wakatsuki, T.
    Nakayama, I.
    Imamura, Y.
    Watanabe, M.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] MIRNA signatures as predictors of resistance to endocrine and HER2 targeted therapy
    Healy, N. A.
    Schiff, R.
    Osborne, C. K.
    Miller, N.
    Kerin, M. J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 : S264 - S264
  • [30] Resistance to HER2 targeted therapy in early breast cancer (EBC): The clinical management of intratumoral heterogeneity (ITH) in HER2 overexpressing EBC
    Argyriadis, A.
    Kalfoutzos, K.
    Khodaverdi, S.
    Braun, S.
    Jackisch, C.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (10) : E43 - E44
12345